TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Cue Biopharma ( (CUE) ).
On November 6, 2025, Cue Biopharma and ImmunoScape announced a strategic collaboration to develop a novel cell therapy approach for solid tumors. This agreement allows ImmunoScape to research, develop, and commercialize molecules from Cue Biopharma’s CUE-100 Series, aiming to advance a ‘Seed-and-Boost’ immunotherapy approach. The collaboration is expected to enhance Cue Biopharma’s focus on autoimmune disease programs and advance its Immuno-STAT platform in oncology, potentially providing a breakthrough in T cell therapy with improved efficacy and tolerability. Cue Biopharma will receive significant financial benefits, including equity in ImmunoScape and royalties from future sales.
The most recent analyst rating on (CUE) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.
Spark’s Take on CUE Stock
According to Spark, TipRanks’ AI Analyst, CUE is a Neutral.
Cue Biopharma’s overall stock score is primarily impacted by its weak financial performance, characterized by persistent losses and negative cash flows. The technical analysis provides a neutral outlook, with no strong momentum signals. The valuation is poor due to a negative P/E ratio and lack of dividend yield, reflecting the company’s current financial struggles. Strategic improvements in cost management and operational efficiency are crucial for future financial health.
To see Spark’s full report on CUE stock, click here.
More about Cue Biopharma
Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing injectable biologics that selectively engage and modulate disease-specific T cells for treating autoimmune diseases and cancer. The company’s proprietary platform, Immuno-STAT, aims to harness the immune system’s potential without broad systemic immune modulation.
Average Trading Volume: 188,323
Technical Sentiment Signal: Sell
Current Market Cap: $55.42M
See more insights into CUE stock on TipRanks’ Stock Analysis page.